Erythropoietin in stroke: quo vadis
- 5 April 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 10 (6), 937-949
- https://doi.org/10.1517/14712598.2010.481435
Abstract
Importance of the field: Recombinant erythropoietin (rEPO) failed in a recent clinical study to protect from damages induced by ischemic stroke. The lack of acute treatments in ischemic stroke and the promising outcome in numerous preclinical studies in vivo demands a more critical evaluation of the future use of EPO as an acute treatment. Areas covered in this review: The current use and administration of rhEPO and its analogs in animal models and the future use of this cytokine in the treatment of ischemic stroke. What the reader will gain: In this review the potential reasons for the failure of EPO in the clinical trial are analysed and whether the preclinical trials sufficiently evaluated the true potential of recombinant EPO and its analogs is assessed. Alternative methods for administration of EPO to enhance its potential as a neuroprotective drug in ischemic stroke are discussed. Take home message: Failure in clinical trial does not necessarily indicate the lack of therapeutic potential of EPO. This review encourages further investigation of the true potential of EPO as a candidate drug for the treatment of ischemic stroke by improved preclinical experimental design and utilization of alternative administration methods.Keywords
This publication has 101 references indexed in Scilit:
- Cerebral Ischemia–Reperfusion Injury in Rats—A 3 T MRI Study on Biphasic Blood–Brain Barrier Opening and the Dynamics of Edema FormationJournal of Cerebral Blood Flow & Metabolism, 2009
- Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic StrokeJournal of Pharmacology and Experimental Therapeutics, 2009
- Update of the Stroke Therapy Academic Industry Roundtable Preclinical RecommendationsStroke, 2009
- Current Status of Neuroprotection for Cerebral IschemiaStroke, 2009
- The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in HumansThe Scientific World Journal, 2009
- Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseBMC Neuroscience, 2008
- Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zoneBMC Neuroscience, 2008
- Survival and proliferative roles of erythropoietin beyond the erythroid lineageExpert Reviews in Molecular Medicine, 2008
- Post‐ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemiaBritish Journal of Pharmacology, 2007
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006